About IPF

• Founded: 2013

• Headquarters: London, United Kingdom

• Strategy: Healthcare debt, primarily Europe

• Thesis: Healthcare assets generate predictable cash flows backed by government reimbursement systems, creating defensive debt opportunities across care delivery, pharmaceuticals, and medical technology.

• Track record: Previous funds include IPF III (€150m, 2019) and IPF IV (€200m, 2021)

• Leadership: Managing Partners Stephen Davies and Frederic Bruyere

IPF closed its latest healthcare debt fund at €241m, marking a 20% increase over its €200m predecessor from 2021. The fund focuses on senior and unitranche debt across European healthcare businesses, with the firm citing expanded market opportunity as justification for larger ticket sizes. The close comes after roughly 18 months in market, a timeline consistent with prior IPF vintages.

The 20% step-up from IPF IV tracks with the broader trend in European specialty debt — funds in the €150–300m range are sizing up incrementally rather than doubling, reflecting LP caution around deployment risk in narrower strategies. Court Square Credit Partners closed its latest healthcare credit fund at $285m in late 2023, also a modest increase from its prior vintage, while Nimbus Healthcare closed oversubscribed at £210m in early 2024. IPF's positioning sits between pure asset-based healthcare lenders and broader healthcare credit opportunists, a lane that has held LP interest as government-backed reimbursement flows remain stable.

The larger ticket-size ambition creates a deployment question worth watching. IPF's historical sweet spot has been €10–25m positions in mid-market care providers and specialty pharma distributors — businesses large enough for institutional debt but small enough to avoid competition from banks and direct lenders with €50m+ minimums. Moving upmarket into €30–40m tickets without stretching into riskier capital structures will require either syndication partnerships or a tighter focus on larger platform businesses. If IPF deploys into the same mid-market segment at higher leverage multiples to justify the larger fund, that would be a shift from the conservative positioning that differentiated prior vintages.

Source: Private Debt Investor